These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 16769933)

  • 1. Microglial activation correlates with severity in Huntington disease: a clinical and PET study.
    Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P
    Neurology; 2006 Jun; 66(11):1638-43. PubMed ID: 16769933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglial activation in presymptomatic Huntington's disease gene carriers.
    Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
    Brain; 2007 Jul; 130(Pt 7):1759-66. PubMed ID: 17400599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging microglial activation in Huntington's disease.
    Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P
    Brain Res Bull; 2007 Apr; 72(2-3):148-51. PubMed ID: 17352938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.
    Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; Piccini P
    Hum Brain Mapp; 2011 Feb; 32(2):258-70. PubMed ID: 21229614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
    Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
    Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers.
    Politis M; Lahiri N; Niccolini F; Su P; Wu K; Giannetti P; Scahill RI; Turkheimer FE; Tabrizi SJ; Piccini P
    Neurobiol Dis; 2015 Nov; 83():115-21. PubMed ID: 26297319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
    Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
    Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
    van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
    Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
    Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
    Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [11C]PK11195 PET imaging of spinal glial activation after nerve injury in rats.
    Imamoto N; Momosaki S; Fujita M; Omachi S; Yamato H; Kimura M; Kanegawa N; Shinohara S; Abe K
    Neuroimage; 2013 Oct; 79():121-8. PubMed ID: 23611861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195.
    Anderson AN; Pavese N; Edison P; Tai YF; Hammers A; Gerhard A; Brooks DJ; Turkheimer FE
    Neuroimage; 2007 May; 36(1):28-37. PubMed ID: 17398120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bradykinesia in early Huntington's disease.
    Sánchez-Pernaute R; Künig G; del Barrio Alba A; de Yébenes JG; Vontobel P; Leenders KL
    Neurology; 2000 Jan; 54(1):119-25. PubMed ID: 10636136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
    Politis M; Giannetti P; Su P; Turkheimer F; Keihaninejad S; Wu K; Waldman A; Malik O; Matthews PM; Reynolds R; Nicholas R; Piccini P
    Neurology; 2012 Aug; 79(6):523-30. PubMed ID: 22764258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180.
    Dickens AM; Vainio S; Marjamäki P; Johansson J; Lehtiniemi P; Rokka J; Rinne J; Solin O; Haaparanta-Solin M; Jones PA; Trigg W; Anthony DC; Airas L
    J Nucl Med; 2014 Mar; 55(3):466-72. PubMed ID: 24516258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrastriatal dopamine D(2) receptor binding in Huntington's disease.
    Esmaeilzadeh M; Farde L; Karlsson P; Varrone A; Halldin C; Waters S; Tedroff J
    Hum Brain Mapp; 2011 Oct; 32(10):1626-36. PubMed ID: 20886576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPECT study of the nigrostriatal dopaminergic system in Huntington's disease.
    Hwang WJ; Yao WJ
    J Neuroimaging; 2013 Apr; 23(2):192-6. PubMed ID: 22211920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
    van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
    Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.